Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

Neurocrine Biosciences has a fifty-two week low of $105.18 and a fifty-two week high of $157.98. The firm has a market capitalization of $10.87 billion, a P/E ratio of 33.13, a P/E/G ratio of 0.77 ...

Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The new indication brings the drug into direct competition with Ongentys from rival Neurocrine Biosciences, which was approved for the same use last year. Adamas noted that Gocovri (amantadine ...

Now Neurocrine Bioscience, with Ingrezza and elagolix not far behind it, could become a significant mid-size company within just a few years. Andrew McConaghie 11 April, 2017 ...

After hours: March 17 at 4:20:00 PM EDT Loading Chart for NBIX ...

After hours: March 14 at 6:49:13 PM EDT ...